anonymous
Guest
anonymous
Guest
And now another change in marketing leadership for respiratory and EyeCare. Who think optha will be selling Xolair next year and respi will be selling Xiidra and combine all? Thoughts?
Was there a memo that went out about marketing leadership changing? I have not seen this….